Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships ...
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutio...
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.